Educating the nursing team was one of the primary elements of the initiative. The hospital system’s shock consortium developed an algorithm to assess and treat patients with cardiogenic shock. Using ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

40 hours with a standard deviation of .37 hours. "Early recognition of patients with cardiogenic shock allows for prompt treatment initiation," the study authors wrote. "Timely intervention can ...

The hospital system's shock consortium developed an algorithm to assess and treat patients with cardiogenic shock. Using the acronym SALUDE, the algorithm guides nurses and other clinicians in ...

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

Progress in assessing cardiovascular risk and identifying early prevention opportunities, improvements in treating heart failure, new therapies for bleeding strokes, strategies for reducing the ...

Johnson & Johnson today announced the FDA has expanded its approval of Impella heart pumps to treat specific pediatric ...

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, ...

Pham Van Quang, head of the Intensive Care and Anti-Poisoning Department, determined that the girl was suffering from ...

also addressing cardiogenic shock under similar clinical conditions. J&J MedTech R&D, ECP and Pediatrics Platform, Heart Recovery senior director Sonya Bhavsar said: “The opportunity to treat ...